Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) Assets Average (2016 - 2026)

Myriad Genetics has reported Assets Average over the past 15 years, most recently at $717.4 million for Q4 2025.

  • Quarterly Assets Average fell 31.97% to $717.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $717.4 million through Dec 2025, down 31.97% year-over-year, with the annual reading at $867.1 million for FY2025, 20.23% down from the prior year.
  • Assets Average was $717.4 million for Q4 2025 at Myriad Genetics, up from $702.7 million in the prior quarter.
  • Over five years, Assets Average peaked at $1.4 billion in Q1 2021 and troughed at $702.7 million in Q3 2025.
  • The 5-year median for Assets Average is $1.2 billion (2023), against an average of $1.1 billion.
  • Year-over-year, Assets Average dropped 3.55% in 2023 and then plummeted 35.13% in 2025.
  • A 5-year view of Assets Average shows it stood at $1.3 billion in 2021, then dropped by 9.26% to $1.2 billion in 2022, then fell by 4.77% to $1.1 billion in 2023, then fell by 8.13% to $1.1 billion in 2024, then tumbled by 31.97% to $717.4 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Assets Average are $717.4 million (Q4 2025), $702.7 million (Q3 2025), and $841.7 million (Q2 2025).